On June 1, 2021, China will implement a drug patent linkage system that will allow drug companies to litigate patent infringement disputes before the marketing approval of competitor drugs. China will also provide patent term adjustments and extensions. Intellectual property lawyers from Paul Hastings and King & Wood Mallesons, along with counsel from Johnson & Johnson, will draw upon their extensive experience in the U.S. and China and offer insights on how to navigate this rapidly developing area. Topics will include the latest developments in China’s drug patent law, patent enforcement strategies under China’s drug patent linkage system, litigation perspectives from what has been learned from the U.S. and corporate patent and business strategies.